Concordia Healthcare to buy therapy product from PE-backed Revive
Concordia Healthcare Corp (TSX: CXR) (OTCQX: CHEHF) has agreed to buy Donnatal(R), a therapy in the treatment of irritable bowel syndrome and acute enterocolitis, from Revive Pharmaceuticals Inc for US$200 million in cash and 4.6 million shares of Concordia. Revive, a Charlottesville, Virginia-based specialty pharmaceutical company formerly known as PBM Pharmaceuticals, is a portfolio investment of U.S. private equity firm PBM Capital Group. The Oakville, Ontario-based Concordia will finance the deal in part through a credit facility of up to US$195 million provided by GE Capital, Healthcare Financial Services and affiliates.
20 March 2014•5 mins read
